Amgen is launching its recently approved Aranesp (darbepoetin alfa) prefilled SureClick autoinjector for patients with anemia associated with CKD and chemotherapy-induced anemia.


The autoinjector’s safety features include a cover that limits needle exposure before and after the subcutaneous injection, audible clicks to signal the start and end of the injection, and a large inspection window that automatically confirms complete delivery of the injection.

Continue Reading


It was approved in the European Union last year for patients with anemia associated with CKD or chemotherapy, and has been delivered to approximately 500,000 patients to date.


“Health-care providers and patients [in the United States] now have a new secure and simple option that automatically delivers a complete subcutaneous injection in a single use,” said Willard Dere, MD, Amgen’s senior vice president for global development and its chief medical officer.